GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » HTG Molecular Diagnostics Inc (OTCPK:HTGMQ) » Definitions » PE Ratio

HTG Molecular Diagnostics (HTG Molecular Diagnostics) PE Ratio : At Loss (As of May. 17, 2024)


View and export this data going back to 2015. Start your Free Trial

What is HTG Molecular Diagnostics PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-17), HTG Molecular Diagnostics's share price is $0.0025. HTG Molecular Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-17.80. Therefore, HTG Molecular Diagnostics's PE Ratio for today is At Loss.

HTG Molecular Diagnostics's EPS (Diluted) for the three months ended in Mar. 2023 was $-2.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-17.80.

As of today (2024-05-17), HTG Molecular Diagnostics's share price is $0.0025. HTG Molecular Diagnostics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-17.80. Therefore, HTG Molecular Diagnostics's PE Ratio without NRI ratio for today is At Loss.

HTG Molecular Diagnostics's EPS without NRI for the three months ended in Mar. 2023 was $-2.28. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-17.80.

HTG Molecular Diagnostics's EPS (Basic) for the three months ended in Mar. 2023 was $-2.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-17.80.

Back to Basics: PE Ratio


HTG Molecular Diagnostics PE Ratio Historical Data

The historical data trend for HTG Molecular Diagnostics's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HTG Molecular Diagnostics PE Ratio Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of HTG Molecular Diagnostics's PE Ratio

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HTG Molecular Diagnostics's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's PE Ratio distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's PE Ratio falls into.



HTG Molecular Diagnostics PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

HTG Molecular Diagnostics's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.0025/-17.800
=-0(At Loss)

HTG Molecular Diagnostics's Share Price of today is $0.0025.
HTG Molecular Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.80.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


HTG Molecular Diagnostics  (OTCPK:HTGMQ) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


HTG Molecular Diagnostics PE Ratio Related Terms

Thank you for viewing the detailed overview of HTG Molecular Diagnostics's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HTG Molecular Diagnostics (HTG Molecular Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a commercial-stage RNA platform-based life sciences company focused on advancing the promise of precision medicine. Its proprietary NGS-adapted chemistry and HTG EdgeSeq platform automates sample processing and can quickly, robustly, and simultaneously profile hundreds or thousands of molecular targets using a relatively small amount of biological samples, in liquid or solid forms. Its products include instruments, consumables, and software that combine to form its HTG EdgeSeq platform. The company's menu of HTG EdgeSeq molecular profiling panels is automated on its HTG EdgeSeq platform, applying genomic sequencing tools to quickly generate gene expression data using its simplified workflow for customers.
Executives
Stephen Barat officer: Senior VP of Therapeutics C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Thomas W. Dubensky director C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
L5 Capital Inc. 10 percent owner 1 FIRST CANADIAN PLACE, 39TH FLOOR, TORONTO A6 M5X 1H3
Christopher P Kiritsy director
Byron Lawson officer: SVP/Chief Commercial Officer C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Tim B Johnson director, officer: President & CEO
Laurence W Lytton 10 percent owner 467 CENTRAL PARK WEST, NY NY 10025
Laura Lee Godlewski officer: VP of Accounting and Reporting C/O HTG MOLECULAR DIAGNOSTICS, INC., 3430 E. GLOBAL LOOP, TUCSON AZ 85706
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Shaun D Mcmeans officer: VP, Finance & Admin. & CFO 3708 E COLUMBIA STREET, SUITE #110, TUCSON AZ 85714-3413
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Nv Qiagen 10 percent owner HULSTERWEG 82, PL VENLO P7 5912
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Don M Hardison director